KR20210107086A - 레시니페라톡신의 투여에 의한 파킨슨병의 치료 방법 - Google Patents

레시니페라톡신의 투여에 의한 파킨슨병의 치료 방법 Download PDF

Info

Publication number
KR20210107086A
KR20210107086A KR1020217023429A KR20217023429A KR20210107086A KR 20210107086 A KR20210107086 A KR 20210107086A KR 1020217023429 A KR1020217023429 A KR 1020217023429A KR 20217023429 A KR20217023429 A KR 20217023429A KR 20210107086 A KR20210107086 A KR 20210107086A
Authority
KR
South Korea
Prior art keywords
aav
rtx
vehicle
mice
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217023429A
Other languages
English (en)
Korean (ko)
Inventor
알렉시스 나하마
헨리 홍준 지
Original Assignee
소렌토 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소렌토 쎄라퓨틱스, 인코포레이티드 filed Critical 소렌토 쎄라퓨틱스, 인코포레이티드
Publication of KR20210107086A publication Critical patent/KR20210107086A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217023429A 2018-12-24 2019-12-23 레시니페라톡신의 투여에 의한 파킨슨병의 치료 방법 Ceased KR20210107086A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862784650P 2018-12-24 2018-12-24
US62/784,650 2018-12-24
US201962914170P 2019-10-11 2019-10-11
US62/914,170 2019-10-11
PCT/US2019/068235 WO2020139797A1 (en) 2018-12-24 2019-12-23 Methods for treating parkinson's disease by administering resiniferatoxin

Publications (1)

Publication Number Publication Date
KR20210107086A true KR20210107086A (ko) 2021-08-31

Family

ID=71126251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217023429A Ceased KR20210107086A (ko) 2018-12-24 2019-12-23 레시니페라톡신의 투여에 의한 파킨슨병의 치료 방법

Country Status (8)

Country Link
US (1) US12201608B2 (https=)
EP (1) EP3902539B1 (https=)
JP (1) JP7519359B2 (https=)
KR (1) KR20210107086A (https=)
CN (1) CN113473983B (https=)
AU (1) AU2019414329A1 (https=)
CA (1) CA3124499A1 (https=)
WO (1) WO2020139797A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108979A (ko) 2018-12-21 2021-09-03 소렌토 쎄라퓨틱스, 인코포레이티드 부적응 통증을 치료하기 위한 레시니페라톡신의 신경 주위 투여
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
JP7530365B2 (ja) 2019-01-22 2024-08-07 ソレント・セラピューティクス・インコーポレイテッド レシニフェラトキシンを投与することによって変形性関節症疼痛を処置するための方法
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
WO2008109026A1 (en) 2007-03-05 2008-09-12 Mt Cook Pharma Pharmaceutical compositions for the localized treatment of neurogenic dysfunction
DK2222289T3 (da) * 2007-11-19 2013-10-07 Nestec Sa Behandling af oral pharyngeal dysphagi
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN105017155B (zh) * 2014-04-16 2017-06-16 华东师范大学 类三环二萜并吡唑衍生物及其制备方法和应用
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
CN107126445A (zh) * 2017-04-20 2017-09-05 江南大学 粪菌移植在治疗帕金森病方面的应用

Also Published As

Publication number Publication date
JP2022514695A (ja) 2022-02-14
US20210299090A1 (en) 2021-09-30
CA3124499A1 (en) 2020-07-02
EP3902539B1 (en) 2024-07-31
CN113473983A (zh) 2021-10-01
EP3902539A4 (en) 2022-08-24
WO2020139797A1 (en) 2020-07-02
EP3902539A1 (en) 2021-11-03
JP7519359B2 (ja) 2024-07-19
AU2019414329A1 (en) 2021-06-10
CN113473983B (zh) 2024-07-23
US12201608B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
US12201608B2 (en) Methods for treating Parkinson's disease by administering resiniferatoxin
TWI289455B (en) Use of botilinum toxin in the manufacture of a medicament for treating a movement disorder via intracanial administration
CA2761156C (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
Maybhate et al. Potential long-term benefits of acute hypothermia after spinal cord injury: assessments with somatosensory-evoked potentials
AU2013295370B2 (en) Use of biotin for the treatment of multiple sclerosis
RU2095060C1 (ru) Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний
KR20050109969A (ko) 보툴리눔 톡신으로 부비동염 관련 만성 안면통 및 두통을치료하는 방법
Niu et al. Effect of bilateral deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease
Reese et al. Motor outcome of dystonic camptocormia treated with pallidal neurostimulation
Yan et al. Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor
WO2012060845A1 (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
ES2972849T3 (es) Tratamiento del dolor neuropático en personas con lesión de la médula espinal
Furukawa et al. Alternating Horner syndrome
Al-Olama et al. Uptake of the antisecretory factor peptide AF-16 in rat blood and cerebrospinal fluid and effects on elevated intracranial pressure
US8633165B2 (en) Neuroprotective effects of 2DG in traumatic brain injury
Guidine et al. Electroencephalographic evidence of brainstem recruitment during scorpion envenomation
Schiff et al. FORCED CIRCLING MOVEMENTS (ADVERSIVE SYNDROME): Correction with Dinenhydrinate (Dramamine)
WO2014005720A1 (en) Use of (r)-phenylpiracetam for the treatment of disease-associated fatigue
US10285935B2 (en) Non-invasive method for direct delivery of therapeutics to the spinal cord in the treatment of spinal cord pathology
Lawless Minocycline plus N-acetylcysteine improve chronic and progressive structural and functional deficits following a single TBI in male mice
Heysieattalab et al. Effects of social hierarchy on innate fear‑induced panic responses
KR20250146635A (ko) 리포좀 폴록사머 복합체를 포함하는 통증 질환 치료 조성물
US20210000782A1 (en) Application of drofenine or salt thereof to preparation of medicine for treating peripheral neuron axonal injury and peripheral related neuropathy
Kim et al. Effect of acupuncture on 6-Hydroxydopamine-induced nigrostriatal dopaminergic neuronal cell death in rats
CN116234579A (zh) 用于治疗神经退行性疾病的包含罗替戈汀和乙酰胆碱酯酶抑制剂的组合药物制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601